WO2011090932A3 - A method of treating sinusitis, including chronic sinusitis - Google Patents

A method of treating sinusitis, including chronic sinusitis Download PDF

Info

Publication number
WO2011090932A3
WO2011090932A3 PCT/US2011/021524 US2011021524W WO2011090932A3 WO 2011090932 A3 WO2011090932 A3 WO 2011090932A3 US 2011021524 W US2011021524 W US 2011021524W WO 2011090932 A3 WO2011090932 A3 WO 2011090932A3
Authority
WO
WIPO (PCT)
Prior art keywords
sinusitis
treating
chronic sinusitis
including chronic
tissue
Prior art date
Application number
PCT/US2011/021524
Other languages
French (fr)
Other versions
WO2011090932A2 (en
Inventor
Howard M. Alliger
Original Assignee
Sinox Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinox Corporation filed Critical Sinox Corporation
Priority to CA2787512A priority Critical patent/CA2787512C/en
Priority to EP11735037.1A priority patent/EP2525802A4/en
Priority to US13/522,570 priority patent/US20130108714A1/en
Publication of WO2011090932A2 publication Critical patent/WO2011090932A2/en
Publication of WO2011090932A3 publication Critical patent/WO2011090932A3/en
Priority to US14/952,221 priority patent/US10201563B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders

Abstract

The present invention relates to a method for treating acute and chronic sinusitis, and in particular, severe chronic sinusitis by exposing affected tissue of the sinus and contiguous tissue in the, nasal cavity and greater oral cavity to effective amounts of chlorine dioxide as a bioactive agent. Compositions and methods of treatment are disclosed herein.
PCT/US2011/021524 2010-01-19 2011-01-18 A method of treating sinusitis, including chronic sinusitis WO2011090932A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2787512A CA2787512C (en) 2010-01-19 2011-01-18 A method of treating sinusitis, including chronic sinusitis
EP11735037.1A EP2525802A4 (en) 2010-01-19 2011-01-18 A method of treating sinusitis, including chronic sinusitis
US13/522,570 US20130108714A1 (en) 2010-01-19 2011-01-18 Method of treating sinusitis, including chronic sinusitis
US14/952,221 US10201563B2 (en) 2010-01-19 2015-11-25 Method of treating sinusitis, including chronic sinusitis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33631910P 2010-01-19 2010-01-19
US61/336,319 2010-01-19
US37223310P 2010-08-10 2010-08-10
US61/372,233 2010-08-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/522,570 A-371-Of-International US20130108714A1 (en) 2010-01-19 2011-01-18 Method of treating sinusitis, including chronic sinusitis
US14/952,221 Continuation US10201563B2 (en) 2010-01-19 2015-11-25 Method of treating sinusitis, including chronic sinusitis

Publications (2)

Publication Number Publication Date
WO2011090932A2 WO2011090932A2 (en) 2011-07-28
WO2011090932A3 true WO2011090932A3 (en) 2011-11-17

Family

ID=44307533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/021524 WO2011090932A2 (en) 2010-01-19 2011-01-18 A method of treating sinusitis, including chronic sinusitis

Country Status (4)

Country Link
US (2) US20130108714A1 (en)
EP (1) EP2525802A4 (en)
CA (1) CA2787512C (en)
WO (1) WO2011090932A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103040860B (en) * 2012-11-29 2018-08-14 刘学武 A kind of method starting mammalian stem cell and chlorine dioxide are in the application for preparing drug for starting mammalian stem cell
EP3886812A4 (en) * 2018-11-29 2022-10-19 Yildiz Teknik Universitesi A nasal solution with closed basin natural spring water characteristic and method for obtaining said nasal solution
JP2023522398A (en) * 2020-04-21 2023-05-30 ライフアクティバス プライベート リミテッド Pharmaceutical Compositions of Chlorine for Treatment of Respiratory Viral Infections
WO2022047188A1 (en) * 2020-08-31 2022-03-03 Madray George William Process of using chlorine dioxide for the attenuation and or treatment of coronavirus diseases
US11179415B1 (en) * 2020-12-18 2021-11-23 George William Madray Process of using chlorine dioxide for the attenuation and/or treatment of Coronavirus diseases such as COVID-19 and disabling, treating or attenuating the SARS CoV-2 virus, and its future infective variants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4084747A (en) * 1976-03-26 1978-04-18 Howard Alliger Germ killing composition and method
US5651996A (en) * 1992-03-04 1997-07-29 Arco Research Co., Inc. Method and compositions for the production of chlorine dioxide
US6039934A (en) * 1998-08-04 2000-03-21 Alliger; Howard Use of xanthan gum for gelling CIO2 and related species
US20040071788A1 (en) * 2002-07-30 2004-04-15 Fuhr Allan H. Nasal hygiene method and composition
US20070196434A1 (en) * 2006-01-20 2007-08-23 Oculus Innovative Sciences, Inc. Methods of preventing or treating sinusitis with oxidative reductive potential water solution

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2623188A (en) * 1987-10-13 1989-05-02 New Generation Products, Inc. Chlorine dioxide germicidal composition
US5489435A (en) * 1993-07-06 1996-02-06 Ratcliff; Perry A. Composition for treatment of abnormal conditions of the epithelium of bodily orifices
US6582682B2 (en) * 2000-10-30 2003-06-24 Noville, Inc. Oral care compositions comprising stabilized chlorine dioxide
US9168318B2 (en) * 2003-12-30 2015-10-27 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and methods of using the same
EP2147676A4 (en) * 2007-03-22 2012-02-22 Taiko Pharmaceutical Co Ltd Allergen inactivator
WO2008117767A1 (en) * 2007-03-27 2008-10-02 Taiko Pharmaceutical Co., Ltd. Therapeutic agent for infectious skin or mucosal disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4084747A (en) * 1976-03-26 1978-04-18 Howard Alliger Germ killing composition and method
US5651996A (en) * 1992-03-04 1997-07-29 Arco Research Co., Inc. Method and compositions for the production of chlorine dioxide
US6039934A (en) * 1998-08-04 2000-03-21 Alliger; Howard Use of xanthan gum for gelling CIO2 and related species
US20040071788A1 (en) * 2002-07-30 2004-04-15 Fuhr Allan H. Nasal hygiene method and composition
US20070196434A1 (en) * 2006-01-20 2007-08-23 Oculus Innovative Sciences, Inc. Methods of preventing or treating sinusitis with oxidative reductive potential water solution

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2525802A4 *

Also Published As

Publication number Publication date
US10201563B2 (en) 2019-02-12
EP2525802A2 (en) 2012-11-28
US20160074432A1 (en) 2016-03-17
CA2787512C (en) 2021-10-19
US20130108714A1 (en) 2013-05-02
WO2011090932A2 (en) 2011-07-28
CA2787512A1 (en) 2011-07-28
EP2525802A4 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
WO2013072932A3 (en) Oral care compositions
PH12015501108A1 (en) Treatment of pulmonary disease
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2418945A4 (en) Mineral salt-sulfonic acid compositions and methods of use
WO2009045356A3 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
WO2014066916A3 (en) Compositions and methods for safe treatment of rhinitis
WO2011119777A3 (en) Compositions and methods for treatment of neurodegenerative disease
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
WO2013034855A3 (en) Combination of carrageenan and c-glycoside and uses thereof
WO2010032011A8 (en) Anti-fungal therapy
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2011090932A3 (en) A method of treating sinusitis, including chronic sinusitis
ZA201101517B (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases,and uses thereof
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
EP2274411A4 (en) Xanthohumol compositions and methods for treating skin diseases or disorders
BR112014010729A2 (en) methods for treating gout attacks
WO2010012386A3 (en) Method for treating hypersensitive teeth
SG10201405392RA (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the same
UA107576C2 (en) Substituted piperidines
TR201900438T4 (en) Non-acylated ghrelin fragments for use in the treatment of Prader-willi syndrome.
WO2012142238A3 (en) Compositions and methods for the treatment of tissue fibrosis
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders
WO2009088992A3 (en) Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
WO2010107791A3 (en) Pyrazinoisoquinoline compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11735037

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2787512

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011735037

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13522570

Country of ref document: US